Last reviewed · How we verify
FB 301
FB 301 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
FB 301 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.
At a glance
| Generic name | FB 301 |
|---|---|
| Sponsor | Freya Biosciences ApS |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, FB 301 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and subsequent lowering of blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FB 301 CI brief — competitive landscape report
- FB 301 updates RSS · CI watch RSS
- Freya Biosciences ApS portfolio CI